Skip to content
OpenCapital
Get started

Amgen AMGN ENBREL — Total revenues

Other product segments

Repatha
$3.02B—
Other products
$1.53B+3.6%
Prolia
$727M-33.8%
EVENITY
$562M+27.1%
TEPEZZA
$490M+28.6%
Otezla
$431M-1.4%
BLINCYTO
$415M+12.2%
Nplate
$412M+31.6%
XGEVA
$411M-27.4%
TEZSPIRE
$343M+20.4%
KYPROLIS
$330M+1.9%
Aranesp
$311M-8.5%
Vectibix
$287M+7.5%
UPLIZNA
$262M+188%
IMDELLTRA/IMDYLLTRA
$258M+219%
KRYSTEXXA
$255M+8.1%

Similar metrics at other companies

Supernus Pharmaceuticals logo
SUPNQelbree — Total revenues
$77.84M+20.2%
Ardelyx logo
ARDXIBSRELA — Total revenues
$70.07M+57.8%
Biogen logo
BIIBBENEPALI — Total Revenue
$106.8M-4.7%
Bristol-Myers Squibb logo
BMYReblozyl — Total Revenues
$735M+29.4%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
ESP
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$212.16B+30.0%
Enterprise value$268.92B+22.9%
P/E27.2×+2.5×
P/S5.7×+1.0×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp
FCF margin23.1%-8.9pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's enbrel — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's ENBREL — total revenues?
Amgen (AMGN) reported ENBREL — total revenues of $320M in Q1 2026.
How has Amgen's ENBREL — total revenues changed year-over-year?
Amgen's ENBREL — total revenues decreased by 37.3% year-over-year, from $510M to $320M.
What is the long-term trend for Amgen's ENBREL — total revenues?
Over 4 years (2021 to 2025), Amgen's ENBREL — total revenues has grown at a -16.0% compound annual growth rate (CAGR), from $4.47B to $2.23B.
What does ENBREL — total revenues mean?
This metric represents the total gross revenue generated from the sale of a specific flagship therapeutic product within the company's immunology portfolio. It reflects the market demand, pricing power, and competitive positioning of this mature asset as it faces potential biosimilar competition and lifecycle management challenges. Tracking this revenue stream is critical for assessing the stability of the company's legacy product base and its contribution to overall corporate cash flow.